SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

XLO

Xilio Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The key catalyst is the XTX501 Phase 1 data expected in Q4 2027, which is over a year away. Near-term focus is on IND filings for XTX602 and XTX701 in Q4 2027 and the Gilead option data package in H1 2027. Cash runway into Q1 2028 provides no immediate financing pressure.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

XLO drug pipeline →

XTX501

● Neutral Named in this press release
Impact
Phase
Phase 1/2
Time to market
XTX501 is in early clinical development (Phase 1/2). Initial Phase 1 data is expected in Q4 2027. If successful, a registrational trial would follow, meaning potential approval is likely several years away (late 2029 or later under an accelerated timeline).
Next catalyst
None dated

What to watchThe next meaningful catalyst for XTX501 is the initial Phase 1 data readout in Q4 2027, more than a year away. In the near term, watch for a trial-in-progress poster at the SITC meeting in November 2026 and any early safety signals. Xilio's cash runway into Q1 2028 provides a long enough runway to reach that data, but the stock may trade on broader pipeline news and quarterly earnings in the interim. The competitive landscape, particularly Innovent/Takeda's more advanced IBI363 program, will be an important benchmark for XTX501's potential.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$8.53
T+0 close · Nov 10, 2026 · via day close
Latest settled
−0.70%
T+1 · $8.47
Vs SPY
−2.02%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $8.53entry
  2. T+1 · 6d ago −0.70%α −2.02% · $8.47
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xilio reported Q3 2026 collaboration revenue of $10.0M (down from $19.1M a year ago) and net loss of $5.9M (improved from $16.3M loss in Q3 2025). The company dosed the first patient in its Phase 1/2 trial for XTX501 and expects to report initial data in Q4 2027. Cash of $122.2M is expected to fund operations into Q1 2028.

Key Financial Metrics

EPS
−$0.30
Revenue
$10.0M
est $4.9M · +103.8% · -47.6% YoY

Key Facts

  • Collaboration and license revenue was $10.0M for Q3 2026, down from $19.1M in Q3 2025.
  • Net loss was $5.9M for Q3 2026, compared to $16.3M net loss in Q3 2025.
  • Cash and cash equivalents were $122.2M as of September 30, 2026, down from $137.5M at year-end 2025.
  • First patient dosed in Phase 1/2 trial for XTX501 (PD-1/masked IL-2 bispecific) in metastatic NSCLC.
  • Initial Phase 1 data for XTX501 expected in Q4 2027.
  • IND filings for XTX602 and XTX701 planned for Q4 2027.
  • Appointed Yariv Houvras, M.D., Ph.D. as chief medical officer in September 2026.
  • Cash runway expected into Q1 2028, excluding potential warrant exercise proceeds of up to $36.2M.

Financial Impact

Revenue decline of $9.1M YoY; net loss improved by $10.4M YoY; cash burn of $15.3M in Q3 2026.

revenuenet losscash position

Risk Factors

  • Revenue is entirely collaboration-based and declined significantly YoY.
  • No approved products or near-term revenue catalysts; all programs are preclinical or early clinical.
  • Potential dilution from Series C warrant exercises (up to $36.2M) in Q4 2026.
  • Clinical-stage biotech with no path to profitability in the near term.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399365

Track record

16 reports on XLO

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +19.92% at T+60 after the May 12, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $7.70 Now $7.70 −0.00% settles Nov 24
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $7.96 Now $7.70 −3.27% settles Nov 23
  3. Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $8.24 Now $7.70 −6.55% settles Nov 19
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $8.53 Now $7.70 −9.73% settles Nov 17
  5. Oct 26, 202621d ago Press Release Neutral 4/10 Entry $7.31 to $8.03 Now $7.70 +5.34% ▲ +9.85% +11.11% vs SPY
  6. Aug 12, 202613w ago 8-K Bullish 7/10 No price data
  7. Aug 12, 202613w ago Press Release Bullish 7/10 Entry $9.05 to $9.41 Now $7.70 −14.92% ▲ +3.98% +4.42% vs SPY
  8. Jun 1, 202624w ago EFFECT Bearish 5/10 Entry $8.25 to $7.70 Now $7.70 +6.67% ▲ +6.67% +3.92% vs SPY
  9. May 27, 202624w ago S-3/A Neutral 4/10 Entry $8.52 to $8.15 Now $7.70 −9.62% ▼ −4.40% −4.35% vs SPY
  10. May 12, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026